CDX-1135

DB17607InvestigationalProtein Based Therapies

CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex). It was investigated in clinical trials for post-cardiopulmonary bypass syndrome and...

Mechanism: Pharmacologically active on Complement C5, Complement C3, and Complement C4-A
Curator reviewed
Code names: BRL 55730 · CDX-1135 · Soluble complement receptor type 1 · TP-10 · YM 203

Resolves to

Compound

UNII2RF4H67MOG

Targets

P01031C5 P01024C3 P0C0L4C4AP0C0L5C4B

What you can answer from here — as of July 08, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with CDX-1135, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account